Oxford Lane Capital Corp vs SELLAS Life Sciences Group Inc. Common Stock — how do they compare? Oxford Lane Capital Corp trades at $8.57 (market cap $835.71M), while SELLAS Life Sciences Group Inc. Common Stock trades at $11.45 (market cap $2.27B). The key difference: SELLAS Life Sciences Group Inc. Common Stock is far larger — about 2.7× Oxford Lane Capital Corp's market cap, and Oxford Lane Capital Corp pays a 28.15% dividend while SELLAS Life Sciences Group Inc. Common Stock pays none. Which is the better fit depends on your goals.
| OXLC | SLS | |
|---|---|---|
Market Cap | $835.71M | $2.27B |
Volume | 1,125,263 | 4,179,659 |
Sector | Financials | Health |
52-Week High | $16.74 | $15.46 |
52-Week Low | $8.15 | $1.39 |
Typical Hold Time | 49 Days | — |
Enterprise Value | $1.23B | $2.14B |
Dividend Yield | 28.15% | — |
Signals from Pluang's Aura AI — not financial advice
OXLC trades at $8.535, up 0.89% on the day, with a bearish technical signal from moving averages. The stock shows a low P/B of 0.81 and a high net income margin of 100.85% for 2025, but recent earnings misses and a sharp decline in 2026 revenue and net profit to negative figures highlight significant volatility. The company maintains a regular dividend payout of $0.20 monthly, supported by financing activities, but faces challenges from operational cash outflows and negative ROE/ROA.
Outlook is cautious due to earnings instability and bearish technicals, though the dividend yield may attract income seekers. Key risks include sustained operational losses, high interest expenses, and reliance on financing for dividends. Analyst consensus is mixed with 50% buy ratings, indicating divided sentiment on recovery potential amid current headwinds.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Oxford Lane Capital Corp. is a non-diversified, closed-end management investment company. Its primary investment objective is to achieve high current income, with a secondary objective of capital appreciation. The company primarily invests in equity and junior debt tranches of collateralized loan obligations (CLOs), which are pools of corporate loans. OXLC is known for its high-yield distribution policy and provides investors with leveraged exposure to the CLO market.
Read more on OXLC →SELLAS Life Sciences is a late-stage clinical biopharmaceutical company developing therapies for cancer. Its programs include a WT1-targeting cancer immunotherapy and a selective CDK9 inhibitor.
Read more on SLS →